Published on

Medicine – Thrombocytosis

Thrombocytosis is a haematological condition characterised by an elevated platelet count, generally defined as greater than 450 × 10⁹/L.

Thrombocytosis may arise from a primary bone marrow disorder or occur as a secondary (reactive) response to another condition.

Important Clinical Principle

The two major categories are primary (clonal) thrombocytosis, particularly essential thrombocythaemia, and secondary (reactive) thrombocytosis, caused by infection, inflammation, splenectomy, malignancy, bleeding, iron deficiency anaemia, trauma and other conditions.

1. Classification of Thrombocytosis

Thrombocytosis Primary (Clonal) Essential Thrombocythaemia Myeloproliferative neoplasm JAK2 / CALR / MPL driver mutations Other myeloid neoplasms Secondary (Reactive) Infection / inflammation Iron deficiency anaemia Malignancy Splenectomy / hyposplenism Bleeding / trauma / surgery Associated thrombosis

2. Primary Thrombocytosis – Essential Thrombocythaemia

Essential thrombocythaemia (ET), sometimes called essential thrombocytosis, is a chronic myeloproliferative neoplasm characterised by sustained elevation of the platelet count due to clonal proliferation of megakaryocytes in the bone marrow.

A. Pathophysiology

ET is commonly associated with acquired driver mutations affecting pathways responsible for megakaryocyte proliferation and platelet production.

Mutation Approximate Frequency
JAK2 V617F50–60%
CALR20–30%
MPL3–5%
Triple-negativeApproximately 10%

These mutations activate signalling pathways involved in megakaryocyte proliferation and platelet production.

B. Clinical Features

Many patients are asymptomatic and diagnosed incidentally following a routine full blood count.

Possible Manifestations

  • Headache and dizziness.
  • Visual disturbances.
  • Erythromelalgia: burning pain, warmth and redness of the hands or feet.
  • Arterial thrombosis, including stroke or myocardial infarction.
  • Venous thrombosis, including deep vein thrombosis or unusual-site thrombosis.
  • Bleeding, particularly with extreme thrombocytosis.
  • Mild splenomegaly in some patients.

C. Important Complications

Thrombosis

Thrombosis is a major complication of ET, although individual risk varies according to factors such as age, previous thrombosis and JAK2 mutation status.

Bleeding

Bleeding may occur in extreme thrombocytosis because of acquired von Willebrand syndrome, particularly when the platelet count exceeds approximately 1,000 × 10⁹/L.

Disease Progression

A small proportion of patients may progress to myelofibrosis or acute myeloid leukaemia.

Examination Pearl: Essential thrombocythaemia may cause both thrombosis and bleeding. Extreme thrombocytosis can produce acquired von Willebrand syndrome.

3. Secondary (Reactive) Thrombocytosis

Reactive thrombocytosis occurs when platelet production increases in response to another disease or physiological stimulus.

It is generally more common than primary thrombocytosis.

A. Infection and Inflammatory Disorders

Inflammation stimulates cytokine production, particularly interleukin-6 (IL-6), which promotes thrombopoietin-mediated platelet production.

Common Causes

  • Acute bacterial infections.
  • Chronic infections, including tuberculosis.
  • Rheumatoid arthritis.
  • Inflammatory bowel disease.
  • Other chronic inflammatory conditions.

Platelet counts often return towards normal after the underlying inflammatory condition resolves.

B. Postsplenectomy or Hyposplenism

The spleen normally sequesters and removes circulating platelets.

After splenectomy, platelet counts may increase because splenic sequestration is reduced.

Thrombocytosis may also occur in functional hyposplenism, including sickle cell disease.

Examination Pearl: Thrombocytosis with Howell–Jolly bodies suggests absent or impaired splenic function.

C. Malignancy

Certain malignancies cause reactive thrombocytosis through inflammatory cytokines and tumour-associated stimulation of platelet production.

Examples

  • Lung carcinoma.
  • Colorectal carcinoma.
  • Ovarian carcinoma.
  • Other solid tumours.

Persistent unexplained thrombocytosis may warrant investigation for an underlying malignancy, guided by age, symptoms, examination and clinical risk factors.

D. Bleeding

Acute or chronic blood loss may stimulate increased platelet production during marrow recovery.

Chronic bleeding may also cause iron deficiency anaemia, which is itself associated with thrombocytosis.

E. Iron Deficiency Anaemia (IDA)

Iron deficiency anaemia is an important cause of reactive thrombocytosis.

Typical Findings

  • Microcytosis.
  • Hypochromia.
  • Reduced ferritin, unless confounded by inflammation.
  • Elevated platelet count in some patients.

The platelet count commonly improves following effective iron replacement.

Important Clinical Association: A patient with microcytic hypochromic anaemia and thrombocytosis should be investigated for iron deficiency.

F. Trauma

Major trauma and tissue injury can trigger an inflammatory response and increased platelet production.

Reactive thrombocytosis may also occur following surgery or during recovery from significant physiological stress.

G. Thrombosis

Thrombocytosis may occur in association with acute thrombotic events because of inflammation or tissue injury.

However, thrombosis may also be a consequence of primary thrombocytosis, especially essential thrombocythaemia.

The relationship should therefore be interpreted in the clinical context rather than assuming thrombosis is always the cause of an elevated platelet count.

4. Summary of Causes

Primary Thrombocytosis Secondary Thrombocytosis
Essential thrombocythaemiaInfection
Other myeloproliferative neoplasmsInflammatory disorders
Polycythaemia veraPostsplenectomy
Prefibrotic primary myelofibrosisHyposplenism
Chronic myeloid leukaemiaMalignancy
—Bleeding
—Iron deficiency anaemia
—Trauma or surgery
—Associated acute thrombosis

5. Clinical Features

Thrombocytosis itself may be asymptomatic.

Symptoms and signs depend on whether the condition is primary or reactive and whether complications occur.

Clinical Feature Possible Significance
Headache, dizzinessMicrovascular symptoms, particularly in ET
ErythromelalgiaSuggests a myeloproliferative neoplasm
Arterial or venous thrombosisPossible ET complication
Unusual bleedingConsider acquired von Willebrand syndrome
FeverInfection or inflammation
Weight loss, night sweatsPossible malignancy or myeloproliferative disease
SplenomegalyMay suggest a myeloproliferative neoplasm
Microcytic anaemiaConsider iron deficiency
Howell–Jolly bodiesHyposplenism

6. Investigations

A. Full Blood Count

The full blood count confirms thrombocytosis and assesses the other blood cell lines.

  • Elevated haemoglobin or haematocrit: Consider polycythaemia vera.
  • Leukocytosis: Infection, inflammation or a myeloproliferative neoplasm.
  • Microcytic anaemia: Iron deficiency.
  • Persistent isolated thrombocytosis: Consider ET after excluding reactive causes.

B. Peripheral Blood Film

The peripheral blood film helps confirm a genuinely elevated platelet count and assess morphology.

  • Increased platelets.
  • Large or giant platelets in some myeloproliferative neoplasms.
  • Microcytic hypochromic red cells in iron deficiency.
  • Howell–Jolly bodies in hyposplenism.
  • Other abnormal cell features suggesting marrow disease.

C. Iron Studies

Serum ferritin and transferrin saturation help identify iron deficiency.

D. Inflammatory Markers

CRP and ESR may be elevated in infection or inflammatory disorders.

E. Molecular Testing

When a myeloproliferative neoplasm is suspected, investigations may include:

  • JAK2 V617F mutation.
  • CALR mutation.
  • MPL mutation.
  • BCR::ABL1 testing when chronic myeloid leukaemia needs exclusion.

F. Bone Marrow Examination

Bone marrow biopsy may be required to distinguish ET from prefibrotic myelofibrosis and other myeloid neoplasms.

ET typically shows increased numbers of enlarged, mature megakaryocytes with characteristic nuclear morphology.

7. Diagnostic Approach

Platelets >450 × 10⁹/L Confirm persistent elevation History, FBC and Blood Film Ferritin, CRP and clinical assessment Reactive Cause Identified? Infection, IDA, inflammation Splenectomy, malignancy, trauma Persistent / Unexplained? JAK2, CALR, MPL BCR::ABL1 when indicated Haematology Assessment Bone marrow biopsy when indicated

8. Management

A. Reactive Thrombocytosis

Treatment focuses on the underlying cause.

Cause Management
InfectionAppropriate antimicrobial treatment when indicated
Inflammatory disorderControl the underlying inflammation
Iron deficiency anaemiaIron replacement and investigation of the cause
MalignancyTreatment of the underlying cancer
PostsplenectomyMonitoring and individualised thrombosis-risk assessment
BleedingIdentify and control the source
TraumaSupportive care and treatment of associated injuries

Routine antiplatelet treatment is generally not indicated solely for reactive thrombocytosis.

B. Essential Thrombocythaemia

Treatment is guided by thrombosis risk, bleeding risk, age, mutation status and clinical history.

Treatment Options

  • Observation in selected very-low-risk patients.
  • Low-dose aspirin when appropriate.
  • Cytoreductive therapy, such as hydroxycarbamide or pegylated interferon alfa, for selected patients.
  • Management of cardiovascular risk factors.
Clinical Warning

Aspirin requires caution in patients with significant bleeding or acquired von Willebrand syndrome. Extreme thrombocytosis should prompt assessment of bleeding risk before antiplatelet treatment.

9. Essential Thrombocythaemia vs Reactive Thrombocytosis

Feature Essential Thrombocythaemia Reactive Thrombocytosis
NatureClonal marrow disorderResponse to another condition
Platelet countPersistently elevated, sometimes markedlyVariable, occasionally markedly elevated
JAK2/CALR/MPLMay be presentUsually absent
Thrombosis riskIncreased, depending on risk factorsUsually driven by underlying condition
SplenomegalyMay occurDepends on cause
Iron deficiencyMay coexistCommon cause
TreatmentRisk-adapted antiplatelet or cytoreductive therapyTreat underlying cause
Important Distinction: The absolute platelet count alone cannot reliably distinguish essential thrombocythaemia from reactive thrombocytosis.

10. High-Yield Examination Summary

Condition Characteristic Association
Essential thrombocythaemiaPersistent thrombocytosis, JAK2/CALR/MPL mutations
InfectionReactive cytokine-mediated platelet production
Inflammatory disordersIL-6 and thrombopoietin stimulation
PostsplenectomyReduced splenic sequestration
HyposplenismHowell–Jolly bodies may be present
MalignancyTumour-associated inflammatory response
BleedingReactive marrow response
Iron deficiency anaemiaMicrocytosis with possible thrombocytosis
TraumaTissue injury and inflammation
ThrombosisMay be associated with reactive changes or be an ET complication

11. Key Examination Pearls

  • Thrombocytosis is generally defined as a platelet count above 450 × 10⁹/L.
  • Essential thrombocythaemia is a chronic myeloproliferative neoplasm.
  • JAK2, CALR and MPL mutations are associated with essential thrombocythaemia.
  • Reactive thrombocytosis is more common than primary thrombocytosis.
  • Infection and inflammation are important reactive causes.
  • Iron deficiency anaemia may produce thrombocytosis despite reduced haemoglobin.
  • Postsplenectomy thrombocytosis results partly from reduced splenic sequestration.
  • Persistent unexplained thrombocytosis requires assessment for a myeloproliferative neoplasm.
  • Extreme thrombocytosis may cause bleeding due to acquired von Willebrand syndrome.
  • Thrombosis is an important complication of essential thrombocythaemia.
Most Important Examination Point

Thrombocytosis with microcytic anaemia suggests iron deficiency; thrombocytosis with Howell–Jolly bodies suggests hyposplenism; and persistent unexplained thrombocytosis with a JAK2, CALR or MPL mutation raises suspicion for essential thrombocythaemia or another myeloproliferative neoplasm.

Clinical Warning

Thrombocytosis accompanied by acute neurological deficits, chest pain, limb ischaemia, suspected venous thromboembolism or significant bleeding requires urgent medical assessment. A markedly elevated platelet count does not exclude bleeding risk.

Kembara Xtra – Medicine Revision Notes

Image description
0 Comments